Citius pharmaceuticals, inc. reports fiscal third quarter 2023 financial results and provides business update

$33.3 million in cash and cash equivalents as of june 30, 2023; runway through august 2024 cranford, n.j. , aug. 14, 2023 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal third quarter ended june 30, 2023.
CTXR Ratings Summary
CTXR Quant Ranking